Microtubule inhibitors power certain ADCs. Biointron highlights how these payloads, combined with antibodies, deliver targeted cancer therapies.
ADCs rely on diverse payloads. Biointron explores cytotoxic drugs and novel mechanisms that expand antibody-drug conjugate applications in oncology and beyond.
Multi-payload ADCs bring new strength to cancer therapy. Biointron explains how combining payloads boosts potency, reduces resistance, and improves patient outcomes.
You can also contact us on the Scientist and Science Exchange marketplaces.
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
Biointron uses cookies and similar technologies to ensure proper website functionality, understand how visitors use our website, and improve our content and services. Necessary cookies are enabled by default.
By clicking “Accept All”, you agree to the use of all cookies, including analytics and optional cookies that help us understand website usage and improve user experience. By clicking “Reject Non-Essential”, only necessary cookies will be used.
You may manage or change your cookie preferences at any time by clicking “Cookie Settings” at the bottom of the website.
For more information about how we use cookies and process personal data, please review our Privacy Policy.
